| Primary information |
|---|
| sequence ID | Seq_6483 |
| Peptide sequence | RAHGQESAIF |
| CancerPDF_ID | CancerPDF_ID3539, CancerPDF_ID9990, |
| PMID | 27026199,21805675 |
| Protein Name | Secreted and transmembrane protein 1,Secreted and transmembrane protein 1 |
| UniprotKB Entry Name | SCTM1_HUMAN,SCTM1_HUMAN |
| Fluid | Urine,Urine |
| M/Z | NA,1115.5425 |
| Charge | NA,NA |
| Mass (in Da) | NA,NA |
| fdr | 1114.52,NA |
| Profiling Technique | "CE-MS, Micro-TOF-MS",MALDI-TOF |
| Peptide Identification technique | MS-MS,MALDI-TOF-MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,1 |
| CancerPDF_ID | CancerPDF_ID3539, CancerPDF_ID9990, |
| p-Value | less than 0.05,NA |
| Software | Proteome Discoverer 1.2,NA |
| Length | 10,10 |
| Cancer Type | Bladder cancer,Muscle-invasive bladder cancer |
| Database | Uniprot Human non-redundant Database,SwissProt Database |
| Modification | NA,NA |
| Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),751 bladder cancer and 127 control |
| Regulation | Differentially expressed between recurrence of UBC vs recurrence control,Differentially expressed between cancer vs normal samples |
| Validation | Independent Validation,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | For testing dataset 88%,NA |
| Specificity | For testing dataset 51%,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |